The FDA has approved two Ziihera (zanidatamab-hrii) regimens for first-line HER2-positive advanced gastroesophageal adenocarcinoma, offering significant survival gains over trastuzumab-based therapy.
Significantly lower all-cause infection rate seen in children receiving daily zinc supplementation versus placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results